Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY12 | Q9H244 | 2/20 | 0.48 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.46 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.46 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.46 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.46 |
| ▸ | DNPH1 | O43598 | 2/20 | 0.45 |
| ▸ | ADORA1 | P30542 | 5/20 | 0.45 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.44 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.43 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.43 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7065329 | 1.00 | P2RY12 (0.48) | P2RY12P2RY2P2RY1P2RY6PRMT6 | |
| SCHEMBL7063482 | 0.92 | P2RY12 (0.47) | P2RY12P2RY2P2RY1P2RY6PRMT6 | |
| SCHEMBL7063487 | 0.92 | P2RY12 (0.47) | P2RY12P2RY2P2RY1P2RY6PRMT6 | |
| SCHEMBL7251722 | 0.92 | P2RY12 (0.46) | P2RY12P2RY2P2RY1P2RY6PRMT6 | |
| SCHEMBL5507017 | 0.92 | P2RY12 (0.46) | P2RY12P2RY2P2RY1P2RY6PRMT6 | |
| SCHEMBL7251211 | 0.92 | P2RY12 (0.47) | P2RY12P2RY2P2RY1P2RY6PRMT6 | |
| SCHEMBL5511440 | 0.92 | P2RY12 (0.47) | P2RY12P2RY2P2RY1P2RY6PRMT6 | |
| SCHEMBL7075682 | 0.90 | P2RY12 (0.58) | P2RY12P2RY2P2RY1P2RY6DNPH1 | |
| SCHEMBL7075684 | 0.90 | P2RY12 (0.58) | P2RY12P2RY2P2RY1P2RY6DNPH1 | |
| SCHEMBL7246178 | 0.89 | P2RY12 (0.44) | P2RY12P2RY2P2RY1P2RY6PRMT6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6624294-B2 | Dissolving nucleoside in solvent to form a solution; cooling; treating with base; warming; reacting with ester to effect alkylation of 2' position of a 2',3'-dihydroxy sugar moiety of a nucleoside | ISIS PHARMACEUTICALS, INC. | 2003-09-23 | — | — | US | disclosed |
| US-20030078415-A1 | Regioselective synthesis of 2'-O-modified nucleosides | IONIS PHARMACEUTICALS, INC. | 2003-04-24 | — | — | US | disclosed |
| US-6403779-B1 | DISSOLVING NUCLEOSIDE IN APROTIC SOLVENT, COOLING, TREATING WITH BASE, WARMING MIXTURE, COOLING, REACTING WITH REACTIVE ESTER TO EFFECT ALKYLATION | ISIS PHARMACEUTICALS, INC. | 2002-06-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030078415-A1 | Regioselective synthesis of 2'-O-modified nucleosides | NSUN2, NT5C3B, RNGTT | P2RY12 4230/4885P2RY2 3378/4885P2RY1 4217/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.